REV-123

N/A

Report date: 2023/02/17 21:03:11

Base Information

Drug NameREV-123
Drug Alias NameREV-123REV123
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSystemix Inc
Active IndicationsN/A
Inactive IndicationsLymphoma

Other Information

ATC CodeN/A
Related LinksN/A